HUTCHMED (China) (HMDCF) Inventory Average (2016 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Inventory Average came in at $41.0 million in Q2 2026, down 8.5% quarter-over-quarter from $44.8 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Inventory Average (2016 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Inventory Average for 9 consecutive years, with $41.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Inventory Average changed N/A year-over-year to $41.0 million in Q2 2026; TTM through Jun 2026 was $41.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $46.2 million, up 66.5% from the prior year.
- Inventory Average was $41.0 million for Q2 2026 at HUTCHMED (China), down from $44.8 million in the prior quarter.
- Over five years, Inventory Average peaked at $55.3 million in Q2 2023 and troughed at $40.8 million in Q2 2022.
- A 4-year average of $46.6 million and a median of $44.8 million in 2025 frame the typical range for Inventory Average.
- Across the five-year window, Inventory Average jumped 80.46% in 2022 and soared 35.36% in 2023, its largest moves.
- Over 4 years, Inventory Average stood at $51.3 million in 2022, then grew by 7.75% to $55.3 million in 2023, then dropped by 18.98% to $44.8 million in 2025, then fell by 8.5% to $41.0 million in 2026.
- The last three Inventory Average figures came in at $41.0 million (Q2 2026), $44.8 million (Q4 2025), and $55.3 million (Q2 2023), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 6.20 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | 1.93 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.77 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 3.09 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | 213.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 90.57 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 2.17 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | 40.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.98 Mn |
| Dec 31, 2025 | 44.79 Mn |
| Jun 30, 2023 | 55.28 Mn |
| Dec 31, 2022 | 51.31 Mn |
| Jun 30, 2022 | 40.84 Mn |
| Jun 30, 2021 | 22.63 Mn |
| Mar 31, 2021 | 19.76 Mn |
| Dec 31, 2020 | 17.51 Mn |
| Dec 31, 2019 | 15.93 Mn |
| Sep 30, 2019 | 14.94 Mn |
| Jun 30, 2019 | 15.92 Mn |
| Mar 31, 2019 | 9.08 Mn |
| Dec 31, 2017 | 5.87 Mn |
| Jun 30, 2017 | 11.75 Mn |
| Dec 31, 2016 | 10.37 Mn |
| Jun 30, 2016 | 8.74 Mn |